{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,21]],"date-time":"2026-07-21T20:16:18Z","timestamp":1784664978904,"version":"3.55.0"},"reference-count":51,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2023,10,1]],"date-time":"2023-10-01T00:00:00Z","timestamp":1696118400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,10,1]],"date-time":"2023-10-01T00:00:00Z","timestamp":1696118400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,10,1]],"date-time":"2023-10-01T00:00:00Z","timestamp":1696118400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2023,10,1]],"date-time":"2023-10-01T00:00:00Z","timestamp":1696118400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2023,10,1]],"date-time":"2023-10-01T00:00:00Z","timestamp":1696118400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2023,10,1]],"date-time":"2023-10-01T00:00:00Z","timestamp":1696118400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2023,10,1]],"date-time":"2023-10-01T00:00:00Z","timestamp":1696118400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["81870166"],"award-info":[{"award-number":["81870166"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Chemico-Biological Interactions"],"published-print":{"date-parts":[[2023,10]]},"DOI":"10.1016\/j.cbi.2023.110687","type":"journal-article","created":{"date-parts":[[2023,8,31]],"date-time":"2023-08-31T00:37:00Z","timestamp":1693442220000},"page":"110687","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":13,"special_numbering":"C","title":["The selective activator protein-1 inhibitor T-5224 regulates the IRF4\/MYC axis and exerts cooperative antimyeloma activity with bortezomib"],"prefix":"10.1016","volume":"384","author":[{"given":"Sishi","family":"Tang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fangrong","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jian","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hang","family":"Dong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qin","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0000-5755-1485","authenticated-orcid":false,"given":"Jing","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yunfeng","family":"Fu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"9983","key":"10.1016\/j.cbi.2023.110687_bib1","doi-asserted-by":"crossref","first-page":"2197","DOI":"10.1016\/S0140-6736(14)60493-1","article-title":"Multiple myeloma","volume":"385","author":"R\u00f6llig","year":"2015","journal-title":"Lancet"},{"issue":"5","key":"10.1016\/j.cbi.2023.110687_bib2","doi-asserted-by":"crossref","first-page":"464","DOI":"10.1001\/jama.2022.0003","article-title":"Diagnosis and management of multiple myeloma: a Review","volume":"327","author":"Cowan","year":"2022","journal-title":"JAMA"},{"issue":"1","key":"10.1016\/j.cbi.2023.110687_bib3","first-page":"56","article-title":"Selinexor, daratumumab, and dexamethasone in patients with relapsed or refractory multiple myeloma","volume":"2","author":"Gasparetto","year":"2020","journal-title":"EJH"},{"issue":"2","key":"10.1016\/j.cbi.2023.110687_bib4","doi-asserted-by":"crossref","first-page":"422","DOI":"10.1038\/s41591-022-02182-7","article-title":"Allogeneic BCMA-targeting CAR T cells in relapsed\/refractory multiple myeloma: phase 1 UNIVERSAL trial interim results","volume":"29","author":"Mailankody","year":"2023","journal-title":"Nat. Med."},{"issue":"10","key":"10.1016\/j.cbi.2023.110687_bib5","doi-asserted-by":"crossref","first-page":"1327","DOI":"10.1016\/S1470-2045(17)30578-8","article-title":"Carfilzomib or bortezomib in relapsed or refractory multiple myeloma (ENDEAVOR): an interim overall survival analysis of an open-label, randomised, phase 3 trial","volume":"18","author":"Dimopoulos","year":"2017","journal-title":"Lancet Oncol."},{"issue":"7","key":"10.1016\/j.cbi.2023.110687_bib6","doi-asserted-by":"crossref","first-page":"1037","DOI":"10.3390\/cancers11071037","article-title":"AP-1 transcription factors as regulators of immune responses in cancer","volume":"11","author":"Atsaves","year":"2019","journal-title":"Cancers"},{"issue":"11","key":"10.1016\/j.cbi.2023.110687_bib7","doi-asserted-by":"crossref","first-page":"859","DOI":"10.1038\/nrc1209","article-title":"AP-1: a double-edged sword in tumorigenesis","volume":"3","author":"Eferl","year":"2003","journal-title":"Nat. Rev. Cancer"},{"issue":"4","key":"10.1016\/j.cbi.2023.110687_bib8","doi-asserted-by":"crossref","first-page":"894","DOI":"10.1038\/sj.onc.1207192","article-title":"Common alterations in gene expression and increased proliferation in recurrent acute myeloid leukemia","volume":"23","author":"Staber","year":"2004","journal-title":"Oncogene"},{"issue":"8","key":"10.1016\/j.cbi.2023.110687_bib9","doi-asserted-by":"crossref","first-page":"3205","DOI":"10.1182\/blood-2002-05-1598","article-title":"JunB gene expression is inactivated by methylation in chronic myeloid leukemia","volume":"101","author":"Yang","year":"2003","journal-title":"Blood"},{"issue":"3","key":"10.1016\/j.cbi.2023.110687_bib10","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1016\/j.humpath.2013.10.024","article-title":"c-JUN N-terminal kinase (JNK) is activated and contributes to tumor cell proliferation in classical Hodgkin lymphoma","volume":"45","author":"Leventaki","year":"2014","journal-title":"Hum. Pathol."},{"issue":"15","key":"10.1016\/j.cbi.2023.110687_bib11","doi-asserted-by":"crossref","first-page":"4104","DOI":"10.1093\/emboj\/cdf389","article-title":"Aberrantly expressed c-Jun and JunB are a hallmark of Hodgkin lymphoma cells, stimulate proliferation and synergize with NF-kappa B","volume":"21","author":"Mathas","year":"2002","journal-title":"EMBO J."},{"issue":"12","key":"10.1016\/j.cbi.2023.110687_bib12","doi-asserted-by":"crossref","first-page":"3509","DOI":"10.1038\/s41375-021-01271-9","article-title":"JunB is a key regulator of multiple myeloma bone marrow angiogenesis","volume":"35","author":"Fan","year":"2021","journal-title":"Leukemia"},{"issue":"16","key":"10.1016\/j.cbi.2023.110687_bib13","doi-asserted-by":"crossref","first-page":"6930","DOI":"10.1021\/jm5004733","article-title":"Small molecule inhibitors targeting activator protein 1(AP-1)","volume":"57","author":"Ye","year":"2014","journal-title":"J. Med. Chem."},{"issue":"7","key":"10.1016\/j.cbi.2023.110687_bib14","doi-asserted-by":"crossref","first-page":"817","DOI":"10.1038\/nbt1412","article-title":"Treatment of arthritis with a selective inhibitor of c-Fos\/activator protein-1","volume":"26","author":"Aikawa","year":"2008","journal-title":"Nat. Biotechnol."},{"issue":"5","key":"10.1016\/j.cbi.2023.110687_bib15","doi-asserted-by":"crossref","first-page":"666","DOI":"10.1111\/cas.12914","article-title":"Selective activator protein-1 inhibitor T-5224 prevents lymph node metastasis in an oral cancer model","volume":"107","author":"Kamide","year":"2016","journal-title":"Cancer Sci."},{"key":"10.1016\/j.cbi.2023.110687_bib16","doi-asserted-by":"crossref","DOI":"10.3389\/fmed.2020.582923","article-title":"A novel miRNA restores the chemosensitivity of AML cells through targeting FosB","volume":"7","author":"Wang","year":"2020","journal-title":"Front. Med."},{"issue":"8","key":"10.1016\/j.cbi.2023.110687_bib17","doi-asserted-by":"crossref","DOI":"10.1002\/ctm2.500","article-title":"Single-cell transcriptomes reveal heterogeneity of high-grade serous ovarian carcinoma","volume":"11","author":"Hao","year":"2021","journal-title":"Clin. Transl. Med."},{"issue":"7201","key":"10.1016\/j.cbi.2023.110687_bib18","doi-asserted-by":"crossref","first-page":"226","DOI":"10.1038\/nature07064","article-title":"IRF4 addiction in multiple myeloma","volume":"454","author":"Shaffer","year":"2008","journal-title":"Nature"},{"issue":"18","key":"10.1016\/j.cbi.2023.110687_bib19","doi-asserted-by":"crossref","first-page":"4771","DOI":"10.1182\/blood-2011-05-356063","article-title":"Cereblon expression is required for the antimyeloma activity of lenalidomide and pomalidomide","volume":"118","author":"Zhu","year":"2011","journal-title":"Blood"},{"issue":"13","key":"10.1016\/j.cbi.2023.110687_bib20","doi-asserted-by":"crossref","first-page":"5987","DOI":"10.1073\/pnas.91.13.5987","article-title":"Identification of binding sites for transcription factors NF-kappa B and AP-2 in the promoter region of the human heme oxygenase 1 gene","volume":"91","author":"Lavrovsky","year":"1994","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"issue":"7","key":"10.1016\/j.cbi.2023.110687_bib21","doi-asserted-by":"crossref","first-page":"2973","DOI":"10.1158\/0008-5472.CAN-09-3407","article-title":"NF-kappaB-inhibited acute myeloid leukemia cells are rescued from apoptosis by heme oxygenase-1 induction","volume":"70","author":"Rushworth","year":"2010","journal-title":"Cancer Res."},{"issue":"2","key":"10.1016\/j.cbi.2023.110687_bib22","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1016\/j.yexcr.2018.01.005","article-title":"Crucial role of HO-1\/IRF4-dependent apoptosis induced by panobinostat and lenalidomide in multiple myeloma","volume":"363","author":"Tang","year":"2018","journal-title":"Exp. Cell Res."},{"issue":"7421","key":"10.1016\/j.cbi.2023.110687_bib23","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1038\/nature11530","article-title":"BATF-JUN is critical for IRF4-mediated transcription in T cells","volume":"490","author":"Li","year":"2012","journal-title":"Nature"},{"issue":"7","key":"10.1016\/j.cbi.2023.110687_bib24","doi-asserted-by":"crossref","first-page":"2059","DOI":"10.1084\/jem.20160514","article-title":"Fra-2 regulates B cell development by enhancing IRF4 and Foxo1 transcription","volume":"214","author":"Ubieta","year":"2017","journal-title":"J. Exp. Med."},{"key":"10.1016\/j.cbi.2023.110687_bib25","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2022.901030","article-title":"JunB is critical for survival of T helper cells","volume":"13","author":"Hsieh","year":"2022","journal-title":"Front. Immunol."},{"issue":"3","key":"10.1016\/j.cbi.2023.110687_bib26","doi-asserted-by":"crossref","first-page":"1341","DOI":"10.3390\/ijms22031341","article-title":"HDAC6-Selective inhibitor overcomes bortezomib resistance in multiple myeloma","volume":"22","author":"Lee","year":"2021","journal-title":"Int. J. Mol. Sci."},{"issue":"26","key":"10.1016\/j.cbi.2023.110687_bib27","doi-asserted-by":"crossref","first-page":"2609","DOI":"10.1056\/NEJMoa030288","article-title":"A phase 2 study of bortezomib in relapsed, refractory myeloma","volume":"348","author":"Richardson","year":"2003","journal-title":"N. Engl. J. Med."},{"issue":"4","key":"10.1016\/j.cbi.2023.110687_bib28","doi-asserted-by":"crossref","first-page":"1692","DOI":"10.1182\/blood-2006-07-037077","article-title":"Gene-expression signature of benign monoclonal gammopathy evident in multiple myeloma is linked to good prognosis","volume":"109","author":"Zhan","year":"2007","journal-title":"Blood"},{"issue":"7","key":"10.1016\/j.cbi.2023.110687_bib29","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1002\/gcc.20668","article-title":"A SNP microarray and FISH-based procedure to detect allelic imbalances in multiple myeloma: an integrated genomics approach reveals a wide gene dosage effect","volume":"48","author":"Agnelli","year":"2009","journal-title":"Genes Chromosomes Cancer"},{"issue":"3","key":"10.1016\/j.cbi.2023.110687_bib52","doi-asserted-by":"crossref","first-page":"621","DOI":"10.1124\/pr.58.3.10","article-title":"Theoretical basis, experimental design, and computerized simulation of synergism and antagonism in drug combination studies","volume":"58","author":"Chou","year":"2006","journal-title":"Pharmacol. Rev."},{"issue":"3","key":"10.1016\/j.cbi.2023.110687_bib30","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1038\/nrm1573","article-title":"Do inducers of apoptosis trigger caspase-independent cell death?","volume":"6","author":"Chipuk","year":"2005","journal-title":"Nat. Rev. Mol. Cell Biol."},{"issue":"4","key":"10.1016\/j.cbi.2023.110687_bib31","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1038\/s41419-019-1551-z","article-title":"Bortezomib-inducible long non-coding RNA myocardial infarction associated transcript is an oncogene in multiple myeloma that suppresses miR-29b","volume":"10","author":"Fu","year":"2019","journal-title":"Cell Death Dis."},{"issue":"1","key":"10.1016\/j.cbi.2023.110687_bib32","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1111\/nyas.13038","article-title":"Multiple myeloma in the marrow: pathogenesis and treatments","volume":"1364","author":"Fairfield","year":"2016","journal-title":"Ann. N. Y. Acad. Sci."},{"issue":"12","key":"10.1016\/j.cbi.2023.110687_bib33","doi-asserted-by":"crossref","first-page":"2347","DOI":"10.1038\/leu.2015.169","article-title":"MMSET regulates expression of IRF4 in t(4;14) myeloma and its silencing potentiates the effect of bortezomib","volume":"29","author":"Xie","year":"2015","journal-title":"Leukemia"},{"issue":"7","key":"10.1016\/j.cbi.2023.110687_bib43","doi-asserted-by":"crossref","first-page":"1570","DOI":"10.1038\/leu.2016.358","article-title":"The AP-1 transcription factor JunB is essential for multiple myeloma cell proliferation and drug resistance in the bone marrow microenvironment","volume":"31","author":"Fan","year":"2017","journal-title":"Leukemia"},{"issue":"8","key":"10.1016\/j.cbi.2023.110687_bib34","doi-asserted-by":"crossref","DOI":"10.1074\/jbc.M113.523746","article-title":"The FOS transcription factor family differentially controls trophoblast migration and invasion","volume":"289","author":"Renaud","year":"2014","journal-title":"J. Biol. Chem."},{"issue":"1","key":"10.1016\/j.cbi.2023.110687_bib35","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1186\/s13059-022-02800-0","article-title":"New roles for AP-1\/JUNB in cell cycle control and tumorigenic cell invasion via regulation of cyclin E1 and TGF-\u03b22","volume":"23","author":"P\u00e9rez-Benavente","year":"2022","journal-title":"Genome Biol."},{"issue":"5","key":"10.1016\/j.cbi.2023.110687_bib36","doi-asserted-by":"crossref","first-page":"915","DOI":"10.1038\/sj.bjc.6604267","article-title":"Growth inhibition of non-small cell lung cancer cells by AP-1 blockade using a cJun dominant-negative mutant","volume":"98","author":"Shimizu","year":"2008","journal-title":"Br. J. Cancer"},{"issue":"4","key":"10.1016\/j.cbi.2023.110687_bib37","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1093\/carcin\/bgv017","article-title":"Aberrantly expressed Fra-1 by IL-6\/STAT3 transactivation promotes colorectal cancer aggressiveness through epithelial-mesenchymal transition","volume":"36","author":"Liu","year":"2015","journal-title":"Carcinogenesis"},{"issue":"7","key":"10.1016\/j.cbi.2023.110687_bib38","doi-asserted-by":"crossref","first-page":"2132","DOI":"10.1158\/0008-5472.CAN-07-6055","article-title":"Activator protein-1 transcription factors are associated with progression and recurrence of prostate cancer","volume":"68","author":"Ouyang","year":"2008","journal-title":"Cancer Res."},{"issue":"1","key":"10.1016\/j.cbi.2023.110687_bib39","first-page":"177","article-title":"Expression of Jun and Fos proteins in ovarian tumors of different malignant potential and in ovarian cancer cell lines","volume":"22","author":"Hein","year":"2009","journal-title":"Oncol. Rep."},{"issue":"4","key":"10.1016\/j.cbi.2023.110687_bib40","doi-asserted-by":"crossref","first-page":"472","DOI":"10.1038\/nm.4310","article-title":"Targeting c-FOS and DUSP1 abrogates intrinsic resistance to tyrosine-kinase inhibitor therapy in BCR-ABL-induced leukemia","volume":"23","author":"Kesarwani","year":"2017","journal-title":"Nat. Med."},{"key":"10.1016\/j.cbi.2023.110687_bib42","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1186\/1471-2407-13-441","article-title":"Expression of activator protein-1 (AP-1) family members in breast cancer","volume":"13","author":"Kharman-Biz","year":"2013","journal-title":"BMC Cancer"},{"issue":"2","key":"10.1016\/j.cbi.2023.110687_bib44","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1038\/s41388-022-02542-0","article-title":"Hypoxia-induced circADAMTS6 in a TDP43-dependent manner accelerates glioblastoma progression via ANXA2\/NF-\u03baB pathway","volume":"42","author":"Zhao","year":"2023","journal-title":"Oncogene"},{"issue":"20","key":"10.1016\/j.cbi.2023.110687_bib45","doi-asserted-by":"crossref","first-page":"3118","DOI":"10.1182\/blood-2014-05-578575","article-title":"The oncogenic transcription factor IRF4 is regulated by a novel CD30\/NF-\u03baB positive feedback loop in peripheral T-cell lymphoma","volume":"125","author":"Boddicker","year":"2015","journal-title":"Blood"},{"issue":"6","key":"10.1016\/j.cbi.2023.110687_bib46","doi-asserted-by":"crossref","first-page":"3120","DOI":"10.4049\/jimmunol.169.6.3120","article-title":"Regulation of IFN regulatory factor 4 expression in human T cell leukemia virus-I-transformed T cells","volume":"169","author":"Sharma","year":"2002","journal-title":"J. Immunol."},{"issue":"3","key":"10.1016\/j.cbi.2023.110687_bib47","doi-asserted-by":"crossref","DOI":"10.1038\/bcj.2016.15","article-title":"Occurrence and prognostic significance of cytogenetic evolution in patients with multiple myeloma","volume":"6","author":"Binder","year":"2016","journal-title":"Blood Cancer J."},{"issue":"6","key":"10.1016\/j.cbi.2023.110687_bib48","doi-asserted-by":"crossref","first-page":"713","DOI":"10.1182\/blood-2015-09-665018","article-title":"Panobinostat plus bortezomib and dexamethasone in previously treated multiple myeloma: outcomes by prior treatment","volume":"127","author":"Richardson","year":"2016","journal-title":"Blood"},{"issue":"4","key":"10.1016\/j.cbi.2023.110687_bib49","doi-asserted-by":"crossref","first-page":"4831","DOI":"10.3390\/ijms13044831","article-title":"Curcumin enhances cytotoxic effects of bortezomib in human multiple myeloma H929 cells: potential roles of NF-\u03baB\/JNK","volume":"13","author":"Bai","year":"2012","journal-title":"Int. J. Mol. Sci."},{"issue":"11","key":"10.1016\/j.cbi.2023.110687_bib50","doi-asserted-by":"crossref","first-page":"2534","DOI":"10.1002\/ijc.28591","article-title":"The effects of cannabidiol and its synergism with bortezomib in multiple myeloma cell lines. A role for transient receptor potential vanilloid type-2","volume":"134","author":"Morelli","year":"2014","journal-title":"Int. J. Cancer"},{"issue":"14","key":"10.1016\/j.cbi.2023.110687_bib51","doi-asserted-by":"crossref","first-page":"3485","DOI":"10.1182\/bloodadvances.2022008345","article-title":"The mitochondrial pyruvate carrier complex potentiates the efficacy of proteasome inhibitors in multiple myeloma","volume":"7","author":"Findlay","year":"2023","journal-title":"Blood Adv."}],"container-title":["Chemico-Biological Interactions"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S000927972300354X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S000927972300354X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,1,8]],"date-time":"2025-01-08T20:43:47Z","timestamp":1736369027000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S000927972300354X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,10]]},"references-count":51,"alternative-id":["S000927972300354X"],"URL":"https:\/\/doi.org\/10.1016\/j.cbi.2023.110687","relation":{},"ISSN":["0009-2797"],"issn-type":[{"value":"0009-2797","type":"print"}],"subject":[],"published":{"date-parts":[[2023,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"The selective activator protein-1 inhibitor T-5224 regulates the IRF4\/MYC axis and exerts cooperative antimyeloma activity with bortezomib","name":"articletitle","label":"Article Title"},{"value":"Chemico-Biological Interactions","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.cbi.2023.110687","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"110687"}}